Augmedix (AUGX) Stock Price
Augmedix Price
Revenue has compounded at 33.5% per year over the past 4 years to 44.86 M USD. Augmedix's net margin stands at -42.7%, up from -158.5% several years earlier. Of 10 analysts, 7 rate the stock a buy — an overall Buy consensus.
Augmedix stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Augmedix over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Augmedix stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Augmedix's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Augmedix Price |
|---|
Augmedix Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Augmedix Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e |
|---|---|---|---|---|---|---|---|---|
| – | 14.00 | 16.00 | 22.00 | 30.00 | 44.00 | 52.00 | 68.00 | 63.00 |
| – | – | 14.29 | 37.50 | 36.36 | 46.67 | 18.18 | 30.77 | -7.35 |
| – | 28.57 | 37.50 | 45.45 | 43.33 | 47.73 | 47.73 | 47.73 | 47.73 |
| 21.00 | 4.00 | 6.00 | 10.00 | 13.00 | 21.00 | 24.82 | 32.45 | 30.07 |
| – | -16.00 | -14.00 | -17.00 | -23.00 | -18.00 | -27.00 | -22.00 | 2.00 |
| – | -114.29 | -87.50 | -77.27 | -76.67 | -40.91 | -51.92 | -32.35 | 3.17 |
| – | -22.00 | -14.00 | -17.00 | -26.00 | -19.00 | -28.00 | -23.00 | -17.00 |
| – | – | -36.36 | 21.43 | 52.94 | -26.92 | 47.37 | -17.86 | -26.09 |
| 49.02 | 1.00 | 26.86 | 34.65 | 37.44 | 49.02 | 49.02 | 49.02 | 49.02 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Augmedix generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Augmedix retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Augmedix's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Augmedix has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Augmedix's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Augmedix stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Augmedix Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Augmedix business model & stock analysis
Augmedix SWOT Analysis
Strengths
One of Augmedix Inc's key strengths is its advanced technology infrastructure, which enables seamless integration of electronic health records (EHR) with augmented reality (AR) technology. This allows for efficient and accurate documentation of patient encounters, saving time and improving doctors' productivity.
Augmedix Inc also benefits from its strong partnerships with leading healthcare systems and facilities. These collaborations provide access to a large customer base and allow the company to continually enhance its product offerings based on real-world feedback from healthcare professionals.
Weaknesses
One of the weaknesses of Augmedix Inc is the relatively high cost associated with implementing their augmented reality technology in healthcare settings. This can limit adoption by smaller healthcare providers with limited resources or budget constraints.
Another weakness is the potential for technical issues or system downtime, which could disrupt doctors' workflow and negatively impact the overall user experience. Augmedix Inc needs to ensure robust technical support and regular system maintenance to address these concerns.
Opportunities
The healthcare industry is continuously evolving, offering numerous opportunities for Augmedix Inc. One such opportunity is the increasing demand for telemedicine and remote patient monitoring, which can be further enhanced through the integration of AR technology.
Augmedix Inc can also explore expansion into international markets, where there is a growing trend towards digital healthcare solutions and adoption of EHR systems. By leveraging its existing technological expertise, the company can tap into these markets to broaden its customer base.
Threats
A major threat for Augmedix Inc is the presence of competitors offering similar augmented reality solutions for healthcare. Rapid technological advancements and market saturation can make it challenging to maintain a competitive edge.
Additionally, regulatory and privacy concerns related to patient data security can pose a threat to Augmedix Inc's operations. Compliance with strict healthcare regulations and data protection laws is crucial to maintain trust among healthcare providers and patients.
Augmedix Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Augmedix historical P/E ratio, EBIT multiple, and P/S ratio
Augmedix annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Augmedix shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Augmedix forecasts and price targets in July 2026
Analyst Price Targets 2026| Δ MOM Price Target | 0.00 % |
| Buy | 70.00 % (7) |
| Hold | 30.00 % (3) |
| Sell | 0.00 % (0) |
| 12M Price Target | 2.98 |
| Last Price | 0.00 |
| Currency | USD |
| 12M Return Potential | 0 % |
| LTM Return | 0 % |
Augmedix Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 11/18/2022 | -0.17USD | 7.87 MUSD | 2022 Q3 |
| 11/14/2022 | -0.17USD | 7.87 MUSD | 2022 Q3 |
Augmedix shareholder structure
| % | Name |
|---|---|
2.71293% | |
1.34393% | |
0.80653% | |
0.53938% | |
0.25112% | |
0.22745% |
Augmedix Executives and Management Board
Mr. Emmanuel Krakaris
(65)President, Chief Executive Officer, Company Secretary, Director · since 2018
Ms. Sandra Breber
(65)Chief Operating Officer
Dr. Saurav Chatterjee
(53)Chief Technology Officer
Mr. William Febbo
(54)Independent Director
Ms. Margie Traylor
(59)Independent Director
Augmedix Supply Chain
Augmedix Supply Chain
Correlation: how closely stock prices move together
| # | Name | 1M | 3M | 6M | 1Y | 2Y | Trend |
|---|---|---|---|---|---|---|---|
| 1 | 0.85 | 0.63 | 0.68 | — | — | ||
| 2 | 0.40 | 0.69 | -0.47 | — | — | ||
| 3 | -0.59 | 0.15 | -0.59 | — | — | ||
| 4 | -0.19 | -0.38 | -0.61 | — | — |
Frequently asked questions about Augmedix
The business model of Augmedix Inc revolves around providing remote medical scribe services to healthcare providers. Augmedix utilizes wearable technology, such as smart glasses, to capture and transmit real-time patient data to professional medical scribes. These scribes then document and transcribe the patient-physician interaction, allowing doctors to focus on patient care. Augmedix's innovative approach enhances physician productivity, reduces administrative burden, and improves healthcare services. By harnessing technology to optimize documentation, Augmedix enables more efficient and accurate patient record-keeping, ultimately leading to improved patient outcomes and streamlined workflows for healthcare providers.
Augmedix stock
Augmedix Peer Group
Augmedix Ticker
Augmedix FIGI
All fundamentals and in-depth analysis of Augmedix
Our stock analysis for Augmedix stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Augmedix. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.